Woodline Partners’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $21.7M | Sell |
498,111
-27,134
| -5% | -$1.18M | 0.11% | 264 |
|
|
2025
Q1 | $14.4M | Sell |
525,245
-12,183
| -2% | -$333K | 0.09% | 297 |
|
|
2024
Q4 | $21.6M | Buy |
537,428
+12,334
| +2% | +$496K | 0.15% | 199 |
|
|
2024
Q3 | $24.9M | Buy |
525,094
+7,297
| +1% | +$345K | 0.21% | 156 |
|
|
2024
Q2 | $15.5M | Buy |
517,797
+16,867
| +3% | +$503K | 0.15% | 197 |
|
|
2024
Q1 | $20.1M | Buy |
500,930
+400,179
| +397% | +$16.1M | 0.19% | 168 |
|
|
2023
Q4 | $2.57M | Sell |
100,751
-2,438
| -2% | -$62.1K | 0.03% | 363 |
|
|
2023
Q3 | $1.43M | Sell |
103,189
-5,592
| -5% | -$77.7K | 0.02% | 418 |
|
|
2023
Q2 | $2.5M | Buy |
108,781
+8,771
| +9% | +$202K | 0.03% | 399 |
|
|
2023
Q1 | $2.96M | Buy |
100,010
+10
| +0% | +$296 | 0.04% | 372 |
|
|
2022
Q4 | $2.5M | Hold |
100,000
| – | – | 0.03% | 448 |
|
|
2022
Q3 | $2.18M | Hold |
100,000
| – | – | 0.03% | 444 |
|
|
2022
Q2 | $1.97M | Buy |
+100,000
| New | +$1.97M | 0.03% | 429 |
|
|
2021
Q4 | – | Sell |
-129,331
| Closed | -$7.6M | – | 749 |
|
|
2021
Q3 | $7.6M | Buy |
129,331
+91,572
| +243% | +$5.38M | 0.12% | 196 |
|
|
2021
Q2 | $1.83M | Buy |
+37,759
| New | +$1.83M | 0.03% | 374 |
|
|
2021
Q1 | – | Sell |
-169,687
| Closed | -$10.5M | – | 451 |
|
|
2020
Q4 | $10.5M | Buy |
169,687
+3,470
| +2% | +$215K | 0.28% | 112 |
|
|
2020
Q3 | $5.37M | Buy |
+166,217
| New | +$5.37M | 0.18% | 124 |
|